Discovery of the Long Interspersed Nuclear Element-1 activation product [Open Reading Frame-1 (ORF1) protein] in human blood
Autor: | Jeremy Gaskins, Saeed A. Jortani, Tyler Yin, James L. Bailen, Keivan Hosseinnejad |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Clinical Biochemistry Enzyme-Linked Immunosorbent Assay Biochemistry Andrology 03 medical and health sciences Prostate cancer 0302 clinical medicine Biopsy medicine Humans Elisa method biology medicine.diagnostic_test Human blood business.industry Biochemistry (medical) Proteins General Medicine medicine.disease Long interspersed nuclear element Open reading frame Prostate-specific antigen 030104 developmental biology Polyclonal antibodies 030220 oncology & carcinogenesis biology.protein business |
Zdroj: | Clinica chimica acta; international journal of clinical chemistry. 487 |
ISSN: | 1873-3492 |
Popis: | Long Interspersed Nuclear Element 1 is the only autonomous mobile DNA capable of self-propagation, and is an environmental biomarker that is activated upon an environmental trigger. We have developed an ELISA method to detect and measure Open Reading Frame-1 (ORF1) and have applied it to interrogate serum samples from men with equivocal prostate specific antigen (PSA) results. Polyclonal antibodies were developed using the first 14-amino acid peptide of N-terminal-ORF1 protein. Remnant serum samples from a total of 53 men, ages>50 yr, were analyzed for immunoreactive ORF1 (iORF1) and PSA concentrations; outcomes for the non-biopsied and biopsied groups were also recorded. The dynamic range of the ELISA was between (CV): 2.0 (14%) to 30 ng/mL (1.2%). The total imprecision (within-run/inter-day) was: QC3 = 2.7%/21%, QC6 = 1.1%/18%, and QC20 = 0.33%/11%. The median iORF1 concentration in the non-biopsy group was 14.7 ng/mL (Q1 – Q3: 10.5 – Q3:18.4), which was significantly lower than the Biopsy group at 25.0 ng/mL (Q1 – Q3: 20.0–33.1), P-value = .003. In conclusion, we have developed a competitive ELISA and discovered the presence of iORF1 in serum, which could be used to advance future studies involving ORF1 measurement from blood. In addition, iORF1 may be a complement with the PSA screen to better detect prostate cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |